They showed that administration of 100 μg/mouse of the anti-TIM-3 antibody daily for 7 days resulted in significant increases in mouse survival in an orthotopic human U87MG glioblastoma model, a syngeneic GL261-PTEN knockout mouse model, and a syngeneic C6 rat model [72]. The gene discussed is HAVCR2; the disease is glioblastoma.